Astellas and Seagen Report Updated Results of Padcev in Two Studies for Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy

 Astellas and Seagen Report Updated Results of Padcev in Two Studies for Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy

Shots:

  • The companies reported the positive results from two studies (EV-201 and EV-103) evaluating Padcev as monothx. and in combination with Merck’s Keytruda in patients with LA or mUC who are not able to receive cisplatin CT respectively
  • An updated analysis of EV-201 Cohort 2 showed that 51% achieved confirmed objective response with CR (22%), mDOR (13.8mos.), mPFS (6.7mos.); OS (16.1mos.) with a median follow up of 16mos. The FDA has granted PR to the supplemental application of Padcev based on these results
  • EV-103 cohort A patients demonstrated a safety profile is consistent with previous findings, with no new safety signals observed. The data will be presented at ASCO2021

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Astellas

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post